Literature DB >> 30603356

Comprehensive risk management of diabetic kidney disease in patients with type 2 diabetes mellitus.

Shin-Ichi Araki1.   

Abstract

Diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus is a leading cause of end-stage renal disease worldwide. An increase in the severity of albuminuria and a decrease in the glomerular filtration rate, by which the DKD stages are categorized, are associated with higher risks of not only end-stage renal disease but also all-cause mortality and cardiovascular mortality. Thus, an optimal management strategy and adequate assessment of therapeutic success are of great clinical and societal relevance to improve the prognosis in patients with type 2 diabetes mellitus and DKD. At present, comprehensive risk management for glycemia, blood pressure, lipid profile, and lifestyle habits is emphasized with respect to cardio-renal protection, rather than one single risk management approach. However, the pharmacological therapy aiming at strict control of these risk factors may be associated with an increased risk of adverse effects, particularly in older adults with diabetes. Accordingly, in the clinical practice of diabetes care, we need to individualize the treatment goals for each risk factor according to the health and social status of each patient with type 2 diabetes mellitus and DKD.

Entities:  

Keywords:  Albuminuria; Comprehensive risk management; Diabetic kidney disease; Multifactorial intervention; Remission; Type 2 diabetes mellitus

Year:  2018        PMID: 30603356      PMCID: PMC6224946          DOI: 10.1007/s13340-018-0351-5

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  2 in total

Review 1.  Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches.

Authors:  Munehiro Kitada; Taro Hirai; Daisuke Koya
Journal:  Diabetol Int       Date:  2020-06-11

2.  Combined effect of sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors for diabetic kidney disease.

Authors:  Shin-Ichi Araki
Journal:  J Diabetes Investig       Date:  2019-10-02       Impact factor: 4.232

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.